Lipocine Inc is a biotechnology business based in the US. Lipocine shares (LPCN) are listed on the NASDAQ and all prices are listed in US Dollars. Lipocine employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Lipocine
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – LPCN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Lipocine stock price (NASDAQ: LPCN)Use our graph to track the performance of LPCN stocks over time.
Lipocine shares at a glance
|Latest market close||$1.22|
|52-week range||$1.09 - $2.42|
|50-day moving average||$1.35|
|200-day moving average||$1.51|
|Wall St. target price||$5.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.55|
Buy Lipocine shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Lipocine stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Lipocine price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||-17.01%|
|3 months (2021-04-30)||-13.48%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
|Gross profit TTM||$-5,053,695|
|Return on assets TTM||-28.84%|
|Return on equity TTM||-75.85%|
|Market capitalisation||$118.3 million|
TTM: trailing 12 months
Shorting Lipocine shares
There are currently 3.5 million Lipocine shares held short by investors – that's known as Lipocine's "short interest". This figure is 9.8% up from 3.2 million last month.
There are a few different ways that this level of interest in shorting Lipocine shares can be evaluated.
Lipocine's "short interest ratio" (SIR)
Lipocine's "short interest ratio" (SIR) is the quantity of Lipocine shares currently shorted divided by the average quantity of Lipocine shares traded daily (recently around 1.0 million). Lipocine's SIR currently stands at 3.39. In other words for every 100,000 Lipocine shares traded daily on the market, roughly 3390 shares are currently held short.
However Lipocine's short interest can also be evaluated against the total number of Lipocine shares, or, against the total number of tradable Lipocine shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lipocine's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Lipocine shares in existence, roughly 40 shares are currently held short) or 0.0406% of the tradable shares (for every 100,000 tradable Lipocine shares, roughly 41 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lipocine.
Find out more about how you can short Lipocine stock.
Lipocine share dividends
We're not expecting Lipocine to pay a dividend over the next 12 months.
Have Lipocine's shares ever split?
Lipocine's shares were split on a 1:100 basis on 24 July 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lipocine shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Lipocine shares which in turn could have impacted Lipocine's share price.
Lipocine share price volatility
Over the last 12 months, Lipocine's shares have ranged in value from as little as $1.09 up to $2.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lipocine's is 0.4412. This would suggest that Lipocine's shares are less volatile than average (for this exchange).
Lipocine Inc. , a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
Stocks similar to Lipocine
Lipocine in the news
Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Clarus, Lipocine announce settlement of patent litigation
Frequently asked questionsWhat percentage of Lipocine is owned by insiders or institutions?
Currently 2.506% of Lipocine shares are held by insiders and 9.506% by institutions. How many people work for Lipocine?
Latest data suggests 13 work at Lipocine. When does the fiscal year end for Lipocine?
Lipocine's fiscal year ends in December. Where is Lipocine based?
Lipocine's address is: 675 Arapeen Drive, Salt Lake City, UT, United States, 84108 What is Lipocine's ISIN number?
Lipocine's international securities identification number is: US53630X1046 What is Lipocine's CUSIP number?
Lipocine's Committee on Uniform Securities Identification Procedures number is: 53630X104
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert